<?xml version="1.0" encoding="US-ASCII" ?>
<rss version="2.0">
<channel>
	<title>FDA Webview</title>
	<description>The leading publisher of FDA News, FDA Review, FDA Compliance, QSR News, and Food Drug Administration information since 1984.</description>
	<link>http://fdaweb.com/</link>
	<lastBuildDate>Thu, 17 May 2012 20:47:49 -0500</lastBuildDate>
	<item>
		<title>Senate Begins Work on User Fee Bill</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121776</link>
		<description>The Senate begins work on the FDA user fee reauthorization bill (S. 3187), with majority leader Harry Reid (D-NV) urging Republicans to not hold up the measure.</description>
		<pubDate>Thu, 17 May 2012 13:05:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121776</guid>
	</item>
	<item>
		<title>PhRMA Objects to DTC &#039;Pre-dissemination&#039; Review Guidance</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121775</link>
		<description>PhRMA says it is concerned that an FDA draft guidance on a mandatory pre-dissemination review program for direct-to-consumer television ads is &quot;overbroad, unduly burdensome, and lacking in narrow, objective, and definitive standards.&quot;</description>
		<pubDate>Thu, 17 May 2012 11:00:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121775</guid>
	</item>
	<item>
		<title>FDA Clears Medgenics IND for Phase 2b Trial to Treat Anemia</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121774</link>
		<description>FDA approves a Medgenics, Inc. IND for a Phase 2b clinical trial of Epodure to produce and deliver erythropoietin for treating anemia in renal dialysis patients.</description>
		<pubDate>Thu, 17 May 2012 10:55:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121774</guid>
	</item>
	<item>
		<title>FDA Posts March NADA, ANADA Approvals</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121773</link>
		<description>Federal Register Final rule: FDA amends the animal drug regulations to reflect March 2012 approval actions and to announce the availability of approval summaries.</description>
		<pubDate>Thu, 17 May 2012 10:52:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121773</guid>
	</item>
	<item>
		<title>FDA Approves 8 Generic Plavix ANDAs</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121772</link>
		<description>FDA announces approval for eight manufacturers of generic Plavix in 75 mg and 300 mg strengths.</description>
		<pubDate>Thu, 17 May 2012 09:25:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121772</guid>
	</item>
	<item>
		<title>Pfizer&#039;s Torisel Misses Endpoint in Renal Cell Carcinoma Trial</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121771</link>
		<description>Pfizer says a Phase 3 study evaluating Torisel (temsirolimus) in patients with advanced renal cell carcinoma, whose disease had progressed on or after Sutent, did not meet the primary endpoint.</description>
		<pubDate>Thu, 17 May 2012 08:38:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121771</guid>
	</item>
	<item>
		<title>FDA Denies OTC Prevacid Bioequivalence Petition</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121770</link>
		<description>FDA says it does not have a policy alleged in a Perrigo petition that always allows applicants for OTC generic drugs to use bioequivalence studies from the branded prescription product. </description>
		<pubDate>Thu, 17 May 2012 06:38:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121770</guid>
	</item>
	<item>
		<title>Reporting Violations Found at Acorda Therapeutics</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121769</link>
		<description>FDA&#039;s New York District Office warns Acorda Therapeutics about its failure to properly report adverse drug experiences.</description>
		<pubDate>Thu, 17 May 2012 06:36:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121769</guid>
	</item>
	<item>
		<title>Avoiding Drug Safety Communication &#039;Fatigue&#039;</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121768</link>
		<description>The American Society of Health-System Pharmacists says it fears that clinicians could become fatigued by receiving too many FDA drug safety communications.</description>
		<pubDate>Thu, 17 May 2012 06:28:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121768</guid>
	</item>
	<item>
		<title>Addendum to ICH Guidance</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121767</link>
		<description>FDA publishes an addendum to a 1997 International Conference on Harmonization guidance on preclinical safety evaluation of biotechnology-derived pharmaceuticals.</description>
		<pubDate>Thu, 17 May 2012 05:34:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121767</guid>
	</item>
	<item>
		<title>FDA Reviewing Zithromax Cardiovascular Safety</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121766</link>
		<description>FDA says it is reviewing safety data on Pfizer&#039;s Zithromax (azithromycin) after a study published in the New England Journal of Medicine  reported a small increase in cardiovascular death associated with the antibiotic.</description>
		<pubDate>Thu, 17 May 2012 05:32:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121766</guid>
	</item>
	<item>
		<title>Global Task Force&#039;s End &#039;No Cause for Concern&#039;</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121765</link>
		<description>CDRH associate director Kimberly Trautman assures an industry conference there&#039;s no  cause for concern about the demise in October of the Global Harmonization Task Force on Medical Devices, and she describes its successor.</description>
		<pubDate>Thu, 17 May 2012 05:08:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121765</guid>
	</item>
	<item>
		<title>FDA Clears Mauna Kea Miniprobes</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121764</link>
		<description>FDA clears Mauna Kea Cellvizio miniprobes.</description>
		<pubDate>Wed, 16 May 2012 16:08:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121764</guid>
	</item>
	<item>
		<title>FDA Approves Drugs Faster than EMA, Health Canada: Study</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121763</link>
		<description>A new study finds that over the last decade, FDA has approved novel therapeutic agents faster than regulators at the European Medicines Agency and Health Canada.</description>
		<pubDate>Wed, 16 May 2012 14:32:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121763</guid>
	</item>
	<item>
		<title>Violations Found in 2009 Mako Surgical Inspection</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121762</link>
		<description>An FDA-483 obtained by FDA Webview details quality and medical device reporting violations from a 2009 Mako Surgical inspection.</description>
		<pubDate>Wed, 16 May 2012 12:49:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121762</guid>
	</item>
	<item>
		<title>Consultants&#039; Advice: Prepare for FDA Inspection</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121761</link>
		<description>RQV Consulting regulatory and compliance specialist Rosario Quintero-Vives says there are seven steps companies should take in advance to ease the stress of an FDA investigation.</description>
		<pubDate>Wed, 16 May 2012 12:41:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121761</guid>
	</item>
	<item>
		<title>Senate Leader Places User Fee Bill on Calendar</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121760</link>
		<description>Senate majority leader Harry Reid (D-NV) places the Health, Education, Labor and Pensions Committee&#039;s recently approved user fee bill (S.3187) on the chamber&#039;s calendar and hopes to begin working on the measure early next week.</description>
		<pubDate>Wed, 16 May 2012 10:58:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121760</guid>
	</item>
	<item>
		<title>Repros Therapeutics Requests Special Protocol Assessment</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121759</link>
		<description>Repros Therapeutics requests a Special Protocol Assessment from FDA for its Androxal Phase 3 pivotal studies.</description>
		<pubDate>Wed, 16 May 2012 10:57:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121759</guid>
	</item>
	<item>
		<title>FDA to Consider Vaccine Trial Cooperative Agreement</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121758</link>
		<description></description>
		<pubDate>Wed, 16 May 2012 10:18:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121758</guid>
	</item>
	<item>
		<title>Importation of Canadian Methotrexate Ends</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5121757</link>
		<description>FDA says Hospira has stopped temporary importing of Canadian-approved methotrexate injection.</description>
		<pubDate>Wed, 16 May 2012 10:17:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5121757</guid>
	</item>
</channel>
</rss>
